Request an invite

Polivy: how was the first human dose set?

polatuzumab vedotin · CD79b
First-in-human starting dose
Not stated in public reviews
NOAEL / key findings
Rat STD10 10 mg/kg; monkey surrogate HNSTD 3 mg/kg; bone marrow, lymphoid, liver, male reproductive organs (testes irreversible)
“The main target organs are bone marrow, lymphoid organs, reproductive organs and liver with less severe effects on eye, skin and pancreas.”
✓ VerifiedEMA assessment report, p. 55Source ↗

Same question, other ADCs

Elahere

mirvetuximab soravtansine · FRα
Rationale not stated; FIH Study 0401 escalated from 0.15 mg/kg (TBW) to 7.0 mg/kg

Enhertu

fam-trastuzumab deruxtecan · HER2
1/12 HED of monkey HNSTD (0.8 mg/kg), also matching minimum effective trough concentration

Kadcyla

ado-trastuzumab emtansine · HER2
HNSTD-based: monkey HNSTD 10 mg/kg (q3w x4), below 1/10 rat severely toxic dose, used to set Phase I start

Zynlonta

loncastuximab tesirine · CD19
1/6 HNSTD in cynomolgus monkey cited as rationale for species choice; actual FIH calculation not detailed

Adcetris

brentuximab vedotin · CD30
Not stated in public reviews

Besponsa

inotuzumab ozogamicin · CD22
Not stated in public reviews

Datroway

datopotamab deruxtecan · Trop-2
Not stated in public reviews

Decnupaz

pivekimab sunirine · CD123
Not stated in public reviews

Emrelis

telisotuzumab vedotin · c-Met
Not stated in public reviews

Mylotarg

gemtuzumab ozogamicin · CD33
Not stated in public reviews

Padcev

enfortumab vedotin · Nectin-4
Not stated in public reviews

Tivdak

tisotumab vedotin · Tissue factor
Not stated in public reviews

Trodelvy

sacituzumab govitecan · Trop-2
Not stated in public reviews

Summary across all 14 ADCs →